Standard

Hyperuricemia correction in men with metabolic syndrome: Acarbose potential. / Reshetnyak, M. V.; Khirmanov, V. N.; Zybina, N. N.; Frolova, M. Yu.

в: Russian Journal of Cardiology, Том 88, № 2, 01.01.2011, стр. 54-58.

Результаты исследований: Научные публикации в периодических изданияхстатьяРецензирование

Harvard

Reshetnyak, MV, Khirmanov, VN, Zybina, NN & Frolova, MY 2011, 'Hyperuricemia correction in men with metabolic syndrome: Acarbose potential', Russian Journal of Cardiology, Том. 88, № 2, стр. 54-58.

APA

Reshetnyak, M. V., Khirmanov, V. N., Zybina, N. N., & Frolova, M. Y. (2011). Hyperuricemia correction in men with metabolic syndrome: Acarbose potential. Russian Journal of Cardiology, 88(2), 54-58.

Vancouver

Reshetnyak MV, Khirmanov VN, Zybina NN, Frolova MY. Hyperuricemia correction in men with metabolic syndrome: Acarbose potential. Russian Journal of Cardiology. 2011 Янв. 1;88(2):54-58.

Author

Reshetnyak, M. V. ; Khirmanov, V. N. ; Zybina, N. N. ; Frolova, M. Yu. / Hyperuricemia correction in men with metabolic syndrome: Acarbose potential. в: Russian Journal of Cardiology. 2011 ; Том 88, № 2. стр. 54-58.

BibTeX

@article{812b54b384ff47fdad8cc7bdd9eeffcf,
title = "Hyperuricemia correction in men with metabolic syndrome: Acarbose potential",
abstract = "The study was aimed at the investigation of “test” (6 days) and longer-term (8 weeks) acarbose treatment effects on plasma uric acid (UA) concentration in patients with metabolic syndrome (MS). Material and methods. In total, 33 men with MS and carbohydrate metabolism disturbances were administered 6-day “test” acarbose therapy. At baseline and 7 days later, saccharose tolerance test was performed, with the measurement of venous plasma levels of fasting UA, fasting fructose, glucose (fasting, 60 and 120 minutes after saccharose load), and insulin (fasting and 120 minutes after the load). 4 weeks later, 20 patients were administered 8-week acarbose therapy, with standard gradual dose increase. At baseline and after the treatment, venous plasma concentrations of UA and fructose were measured. Results. Hyperfructosemia was observed in 100% of the patients, with mean plasma fructose concentration of 0,82±0,97 mmol/l. Hyperuricemia was observed in 51,5% (n=17), with mean plasma UA concentration of 413,2±86,5 mmol/l. Six-week acarbose therapy resulted in a significant decrease of UA levels (p=0,0015) and fructose levels (p=0,049), as well as in postprandial levels of glucose (p=0,03) and insulin (p=0,013). Eight-week acarbose therapy was associated with mean decrease of plasma UA concentration by 5,8% (p=0,04), but no significant changes in fasting plasma levels of fructose (p>0,05).",
keywords = "Acarbose, Diabetes mellitus, Fructose, Hyperuricemia, Impaired glucose tolerance, Metabolic syndrome",
author = "Reshetnyak, {M. V.} and Khirmanov, {V. N.} and Zybina, {N. N.} and Frolova, {M. Yu}",
year = "2011",
month = jan,
day = "1",
language = "English",
volume = "88",
pages = "54--58",
journal = " РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ",
issn = "1560-4071",
publisher = "Russian Society of Cardiology",
number = "2",

}

RIS

TY - JOUR

T1 - Hyperuricemia correction in men with metabolic syndrome: Acarbose potential

AU - Reshetnyak, M. V.

AU - Khirmanov, V. N.

AU - Zybina, N. N.

AU - Frolova, M. Yu

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The study was aimed at the investigation of “test” (6 days) and longer-term (8 weeks) acarbose treatment effects on plasma uric acid (UA) concentration in patients with metabolic syndrome (MS). Material and methods. In total, 33 men with MS and carbohydrate metabolism disturbances were administered 6-day “test” acarbose therapy. At baseline and 7 days later, saccharose tolerance test was performed, with the measurement of venous plasma levels of fasting UA, fasting fructose, glucose (fasting, 60 and 120 minutes after saccharose load), and insulin (fasting and 120 minutes after the load). 4 weeks later, 20 patients were administered 8-week acarbose therapy, with standard gradual dose increase. At baseline and after the treatment, venous plasma concentrations of UA and fructose were measured. Results. Hyperfructosemia was observed in 100% of the patients, with mean plasma fructose concentration of 0,82±0,97 mmol/l. Hyperuricemia was observed in 51,5% (n=17), with mean plasma UA concentration of 413,2±86,5 mmol/l. Six-week acarbose therapy resulted in a significant decrease of UA levels (p=0,0015) and fructose levels (p=0,049), as well as in postprandial levels of glucose (p=0,03) and insulin (p=0,013). Eight-week acarbose therapy was associated with mean decrease of plasma UA concentration by 5,8% (p=0,04), but no significant changes in fasting plasma levels of fructose (p>0,05).

AB - The study was aimed at the investigation of “test” (6 days) and longer-term (8 weeks) acarbose treatment effects on plasma uric acid (UA) concentration in patients with metabolic syndrome (MS). Material and methods. In total, 33 men with MS and carbohydrate metabolism disturbances were administered 6-day “test” acarbose therapy. At baseline and 7 days later, saccharose tolerance test was performed, with the measurement of venous plasma levels of fasting UA, fasting fructose, glucose (fasting, 60 and 120 minutes after saccharose load), and insulin (fasting and 120 minutes after the load). 4 weeks later, 20 patients were administered 8-week acarbose therapy, with standard gradual dose increase. At baseline and after the treatment, venous plasma concentrations of UA and fructose were measured. Results. Hyperfructosemia was observed in 100% of the patients, with mean plasma fructose concentration of 0,82±0,97 mmol/l. Hyperuricemia was observed in 51,5% (n=17), with mean plasma UA concentration of 413,2±86,5 mmol/l. Six-week acarbose therapy resulted in a significant decrease of UA levels (p=0,0015) and fructose levels (p=0,049), as well as in postprandial levels of glucose (p=0,03) and insulin (p=0,013). Eight-week acarbose therapy was associated with mean decrease of plasma UA concentration by 5,8% (p=0,04), but no significant changes in fasting plasma levels of fructose (p>0,05).

KW - Acarbose

KW - Diabetes mellitus

KW - Fructose

KW - Hyperuricemia

KW - Impaired glucose tolerance

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84933041600&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84933041600

VL - 88

SP - 54

EP - 58

JO - РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ

JF - РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ

SN - 1560-4071

IS - 2

ER -

ID: 125110476